跳至主要内容
临床试验/CTRI/2026/02/104786
CTRI/2026/02/104786尚未招募3 期

A comparative clinical trial to evaluate the effect of Vyoshadi Guggulu and Amritadi Guggulu in the management of Prediabetes

Anjaly Peius1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年3月25日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1

研究概览

简要总结

In Asian countries, India has been projected as the country with the fastest growing population of diabetic patients and in terms of “Diabetes capital of the world” Diabetes prevalence is increasing rapidly in the present scenario. Globally an estimated 422 million adults are living with diabetes, the number is projected to almost double by 2030(American diabetes association).The Global prevalence of prediabetes is 5.8% in 2021 will increase upto 6.5% in 2045. Tamil Nadu experienced the highest incidence rate in 2021 with 392.41 per 100,000 and prevalence is 8.3%. In India, around 77 million people above the age of 18 years are suffering from diabetes  and nearly 25 million are prediabetics . The prevalence of prediabetes in India is 22.25% (2025).The growing burden of prediabetes underscores the importance of effectively implementing diabetes prevention policies and interventions. Lifestyle modifications alone often lack sustainability without holistic support.Many patients in the prediabetic stage are unwilling to start allopathic medication or adhere to diet and exercise plans,  increasing the urgency for alternative approaches. Hence, Ayurvedic interventions offer a natural, personalized, and sustainable alternative for prevention and reversal effective prevention, especially in low-income countries, is needed to slow the diabetes epidemic.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 69.00 Year(s)(—)
性别
All

入选标准

  • Subjects fulfilling the following diagonostic criteria that is FBS is 100 to 125 mg/dl or HbA1c between 5.7 and 6.4 percent.
  • sample comes under moderate risk and high risk groups according to IDRS Scale.
  • Sample who fulfill the criteria and willing to sign written informed consent for participation.

排除标准

  • Known case of diabetes mellitus that is greater than or equal to 126 mg/dl or HbA1C greater than or equal to 6.5 percent.
  • Current use of Antidiabetic medications and Insulin Known case of Renal failure,Cardio vascular disease or Cancer.
  • Pregnant ladies and lactating mothers.
  • Severe psychiatric illness or cognitive disorders interfering with compliance.
  • People with alcohol dependency and drug dependency.

研究者

发起方
Anjaly Peius
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Anjaly Peius

Sri Jayendra Saraswathi Ayurveda College and Hospital,Chennai,Tamilnadu

研究点 (1)

Loading locations...

相似试验